Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02054741 (A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Systematic review of patient-reported outcome item libraries in cancer research: an EORTC Quality of Life Group study.Journal of the National Cancer Institute · 2026Pooled it
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Guideline
- Prevalence of patient-reported and clinician-graded cognitive symptomatic adverse events in older patients with advanced cancer.JNCI cancer spectrum · 2026Trial
- Unsupervised learning to identify symptom clusters in older adults undergoing chemotherapy.Journal of geriatric oncology · 2025Trial
- An Unsupervised Machine Learning Approach to Evaluating the Association of Symptom Clusters With Adverse Outcomes Among Older Adults With Advanced Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Article
- Review
- Nurse-led remote symptom management for chemotherapy toxicity and quality of life in lymphoma: a quasi-experimental study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Acceptability of a practical geriatric assessment intervention with older adult cancer survivors and community health workers/promotoras: a qualitative investigation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Review
- National Cancer Institute Cancer Treatment Tolerability Consortium: Current status and future directions.Cancer · 2025Article
- Article
- CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.Journal for immunotherapy of cancer · 2025Review
- Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP).Journal of the National Cancer Institute. Monographs · 2025Article
- Article
- Precision Oncology in Older Cancer Patients: A Single-Center Experience.International journal of molecular sciences · 2024Article
- Geriatric Oncology: A 5-Year Strategic Plan.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2024Review
- Care Delivery Interventions for Individuals with Cancer: A Literature Review and Focus on Gastrointestinal Malignancies.Healthcare (Basel, Switzerland) · 2023Review
- Geriatric assessment and management: is decreasing treatment toxicity good enough?Journal of the National Cancer Institute · 2023Article
- Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
Abstract
purposeProviding a geriatric assessment (GA) summary with management recommendations to oncologists reduces clinician-rated toxicity in older patients with advanced cancer receiving treatment. This secondary analysis of a national cluster randomized clinical trial (ClinicalTrials.gov identifier: NCT02054741) aims to assess the effects of a GA intervention on symptomatic toxicity measured by Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE).
methodsFrom 2014 to 2019, the study enrolled patients age ≥ 70 years, with advanced solid tumors or lymphoma and ≥ 1 GA domain impairment, who were initiating a regimen with high prevalence of toxicity. Patients completed PRO-CTCAEs, including the severity of 24 symptoms (11 classified as core symptoms) at enrollment, 4-6 weeks, 3 months, and 6 months. Symptoms were scored as grade ≥ 2 (at least moderate) and grade ≥ 3 (severe/very severe). Symptomatic toxicity was determined by an increase in severity during treatment. A generalized estimating equation model was used to assess the effects of the GA intervention on symptomatic toxicity.
resultsMean age was 77 years (range, 70-96 years), 43% were female, and 88% were White, 59% had GI or lung cancers, and 27% received prior chemotherapy. In 706 patients who provided PRO-CTCAEs at baseline, 86.1% reported at least one moderate symptom and 49.7% reported severe/very severe symptoms at regimen initiation. In 623 patients with follow-up PRO-CTCAE data, compared with usual care, fewer patients in the GA intervention arm reported grade ≥ 2 symptomatic toxicity (overall: 88.9%
conclusionIn the presence of a high baseline symptom burden, a GA intervention for older patients with advanced cancer reduces patient-reported symptomatic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.